Brian Koopman - Utah Medical Principal Financial Officer
| UTMD Stock | USD 64.57 0.39 0.61% |
Executive
Mr. Brian L. Koopman is the Principal Financial Officer of Utah Medical Products, Inc. since 2018.
| Age | 54 |
| Tenure | 6 years |
| Address | 7043 South 300 West, Midvale, UT, United States, 84047-1048 |
| Phone | 801 566 1200 |
| Web | https://www.utahmed.com |
Brian Koopman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Koopman against Utah Medical stock is an integral part of due diligence when investing in Utah Medical. Brian Koopman insider activity provides valuable insight into whether Utah Medical is net buyers or sellers over its current business cycle. Note, Utah Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Utah Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Koopman over two weeks ago Acquisition by Brian Koopman of 500 shares of Utah Medical at 64.09 subject to Rule 16b-3 | ||
Brian Koopman over a month ago Acquisition by Brian Koopman of 500 shares of Utah Medical at 74.64 subject to Rule 16b-3 | ||
Brian Koopman over three months ago Disposition of tradable shares by Brian Koopman of Utah Medical at 71.61 subject to Rule 16b-3 | ||
Brian Koopman over six months ago Disposition of 366 shares by Brian Koopman of Utah Medical at 101.88 subject to Rule 16b-3 |
Utah Medical Management Efficiency
The company has return on total asset (ROA) of 0.0818 % which means that it generated a profit of $0.0818 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1231 %, meaning that it created $0.1231 on every $100 dollars invested by stockholders. Utah Medical's management efficiency ratios could be used to measure how well Utah Medical manages its routine affairs as well as how well it operates its assets and liabilities. At present, Utah Medical's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, Utah Medical's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to 0.95, whereas Non Currrent Assets Other are projected to grow to (0.95).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Daniel Ackerman | AptarGroup | 51 | |
| JD CFA | Akoya Biosciences | N/A | |
| Niro Ramachandran | Akoya Biosciences | 49 | |
| Jonathan Ngau | LeMaitre Vascular | 50 | |
| Thomas Adams | Repro Med Systems | 51 | |
| Maik Helmers | LeMaitre Vascular | 50 | |
| Valerie StorchWillhaus | AtriCure | N/A | |
| Jeffrey DiRubio | Precision Optics, | N/A | |
| Andy Molnar | Milestone Scientific | 62 | |
| Jeanie Latz | InfuSystems Holdings | N/A | |
| Clay Schwabe | Precision Optics, | N/A | |
| Brian Lloyd | Merit Medical Systems | 63 | |
| Marry Skafidas | AptarGroup | N/A | |
| Paul Grass | Akoya Biosciences | N/A | |
| JD CCEP | AtriCure | 53 | |
| Scott Centea | AngioDynamics | 45 | |
| Saleem Cheeks | AngioDynamics | N/A | |
| David Hissong | LeMaitre Vascular | N/A | |
| Jennifer Kamocsay | Akoya Biosciences | 53 | |
| Rob Cannon | Repro Med Systems | N/A | |
| Mahesh Lawande | Precision Optics, | 51 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0818 |
Utah Medical Products Leadership Team
Elected by the shareholders, the Utah Medical's board of directors comprises two types of representatives: Utah Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Utah. The board's role is to monitor Utah Medical's management team and ensure that shareholders' interests are well served. Utah Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Utah Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Koopman, Principal Financial Officer | ||
| Marcena Clawson, Head Sales | ||
| Kevin Cornwell, Chairman, CEO and President Secretary and Member of Executive Committee | ||
| Mark Fox, Vice Marketing |
Utah Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Utah Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0818 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 129.52 M | ||||
| Shares Outstanding | 3.39 M | ||||
| Shares Owned By Insiders | 6.89 % | ||||
| Shares Owned By Institutions | 73.64 % | ||||
| Number Of Shares Shorted | 56.8 K | ||||
| Price To Earning | 31.38 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Utah Medical Products is a strong investment it is important to analyze Utah Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Utah Medical's future performance. For an informed investment choice regarding Utah Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Utah Medical Products. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Utah Medical. If investors know Utah will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Utah Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Dividend Share 1.2 | Earnings Share 4.28 | Revenue Per Share 12.392 | Quarterly Revenue Growth (0.20) |
The market value of Utah Medical Products is measured differently than its book value, which is the value of Utah that is recorded on the company's balance sheet. Investors also form their own opinion of Utah Medical's value that differs from its market value or its book value, called intrinsic value, which is Utah Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Utah Medical's market value can be influenced by many factors that don't directly affect Utah Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Utah Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Utah Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Utah Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.